Provincial Government of Ontario and Federal Government of Canada

Health Canada vide SNDS (control # 171255), dated 2014/01/08 has decided:

"The pivotal trial submitted in support of this proposed indication demonstrated a statistically significant and clinically relevant improvement in progression free survival (PFS) of AVASTIN in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin over paclitaxel, topotecan or pegylated liposomal doxorubicin alone (absolute gain of 3.4 months in median PFS). These results were supported by an improvement in objective response rate (ORR) (partial responses) in the AVASTIN with chemotherapy treatment arm. The overall survival benefit was numerically in favour of the AVASTIN with chemotherapy treatment arm but the results were not statistically significant.

As expected, patients treated with AVASTIN resulted in increased safety findings compared to patients who received chemotherapy alone. However, the overall safety profile of AVASTIN in this population of patients appears to be consistent with the known safety profile of AVASTIN and is consistent with the experience of AVASTIN across indications. All safety concerns were adequately captured in the Product Monograph (PM).

In view of the clinically meaningful PFS benefit associated with an ORR improvement in the context of this recurrent disease and a serious but identified safety profile, the overall risk benefit profile of AVASTIN appears to be favorable for the treatment of recurrent platinum-resistant ovarian cancer in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin in patients that have received no more than two prior chemotherapy regimens."

1. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds_sdr_avastin_171255-eng.php

I support the efforts of Manjeet Bhullar and all others similarly afflicted with Platinum Resistant Recurrent Ovarian Cancer, and kindly request that the government of Ontario may please allow the drug Avastin (Bevacizumab), Anti-neoplastic agent, manufactured by Hoffmann-La Roche Limited to be:

a) fully funded and covered by OHIP, for at least the first deemed minimum trial doses, and if proven effective for the full treatment of the responding patients,

b) covered under Trillium Drug Program/Ontario Drug Benefits for the patients having no private insurance coverage and are in low income group,

c) declared a tax-deductible Medical Expense.

I also authorize Manjeet Bhullar or his designate to compile and submit this request for the above cited purpose only on my behalf for onward submission to the Government.

GoPetition respects your privacy.

The Support Avastin Funding in Ontario for treatment of recurrent Platinum sensitive Ovarian Cancer petition to Provincial Government of Ontario and Federal Government of Canada was written by Manjeet Bhullar and is in the category Health at GoPetition.